

4. **Stejskal J, Jašková V, Pavličko A, et al.** Diagnostika karcinomu prostaty pomocí fúzní biopsie. *Ces Urol* 2018; 22(2): 87–98.
5. **Kudláčková Š, Zátūra F, Tüdös Z.** Cílená biopsie prostaty pomocí magnetické rezonance – 1. část. *Urol. praxi* 2017; 18(2): 69–72.
6. **Ahmed HU, El-Shater Bosaily A, Brown LC, et al.** Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet*. 2017; 389(10071): 815–822.
7. **Benson MC, Whang IS, Pantuck A, et al.** Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. *J Urol*. 1992; 147(3 Pt 2): 815–816.
8. **Padhani AR, Weinreb J, Rosenkrantz AB, et al.** Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. *Eur Urol*. 2019; 75(3): 385–396.
9. **Venderink W, van Luijckelaar A, Bomers JG, et al.** Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer. *Eur Urol*. 2018; 73(3): 353–360.
10. **Barentsz JO, Richenberg J, Clements R, et al.** ESUR prostate MR guidelines 2012. *Eur Radiol*. 2012; 22(4): 746–757.
11. **Jelidi A, Ohana M, Labani A, et al.** Prostate cancer diagnosis: Efficacy of a simple electromagnetic MRI-TRUS fusion method to target biopsies. *Eur J Radiol*. 2017; 86: 127–134.
12. **Epstein JI, Walsh PC, Carmichael M, Brendler CB.** Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. *JAMA* 1994; 271(5): 368–374.
13. **Simmons LAM, Kanthabalan A, Arya M, et al.** The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. *Br J Cancer* 2017; 116(9): 1159–1165.
14. **Kotb AF, Spaner S, Crump T, Hyndman ME.** The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy. *World J Urol*. 2018; 36(12): 2021–2025.
15. **Schoots IG.** MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions? *Transl Androl Urol*. 2018; 7(1): 70–82.
16. **Distler FA, Radtke JP, Bonekamp D, et al.** The Value of PSA Density in Combination with PI-RADS for the Accuracy of Prostate Cancer Prediction. *J Urol*. 2017; 198(3): 575–582.
17. **Washino S, Okochi T, Saito K, et al.** Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients. *BJU Int*. 2017; 119(2): 225–233.
18. **Hansen NL, Barrett T, Koo B, et al.** The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting. *BJU Int*. 2017; 119(5): 724–730.
19. **Brizmohun Appayya M, Adshead J, Ahmed HU, et al.** National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection – recommendations from a UK consensus meeting. *BJU Int*. 2018; 122(1): 13–25.
20. **Alberts AR, Roobol MJ, Drost FH, et al.** Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. *BJU Int*. 2017; 120(4): 511–519.
21. **Esses SJ, Taneja SS, Rosenkrantz AB.** Imaging Facilities' Adherence to PI-RADS v2 Minimum Technical Standards for the Performance of Prostate MRI. *Acad Radiol*. 2018; 25(2): 188–195.
22. **Sonn GA, Fan RE, Ghanouni P, et al.** Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. *Eur Urol Focus*. 2017; S2405–4569(17): 30266–30273.